Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Cellectis ADR (NASDAQ: CLLS) closed at $1.48 down -1.99% from its previous closing price of $1.51. In other words, the price has decreased by -$1.99 from its previous closing price. On the day, 0.21 million shares were traded. CLLS stock price reached its highest trading level at $1.525 during the session, while it also had its lowest trading level at $1.46.
Ratios:
For a deeper understanding of Cellectis ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.79. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.78. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bryan Garnier on March 17, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
On May 18, 2022, Robert W. Baird Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $10.
Wells Fargo Downgraded its Overweight to Equal Weight on January 06, 2022, whereas the target price for the stock was revised from $39 to $16.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLLS now has a Market Capitalization of 164248928 and an Enterprise Value of 78919936. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.67 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 2.19 whereas that against EBITDA is -1.174.
Stock Price History:
The Beta on a monthly basis for CLLS is 3.07, which has changed by -0.459854 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, CLLS has reached a high of $3.38, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is -18.95%, while the 200-Day Moving Average is calculated to be -32.41%.
Shares Statistics:
For the past three months, CLLS has traded an average of 124.99K shares per day and 296770 over the past ten days. A total of 100.09M shares are outstanding, with a floating share count of 69.26M. Insiders hold about 3.93% of the company’s shares, while institutions hold 13.62% stake in the company. Shares short for CLLS as of 1735603200 were 203458 with a Short Ratio of 1.63, compared to 1732838400 on 131398. Therefore, it implies a Short% of Shares Outstanding of 203458 and a Short% of Float of 0.25.
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Cellectis ADR (CLLS) in the stock market.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.7 and -$0.7 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.76, with 1.0 analysts recommending between -$0.76 and -$0.76.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $20.42M this quarter.It ranges from a high estimate of $77.05M to a low estimate of $2.89M. As of the current estimate, Cellectis ADR’s year-ago sales were $1.86MFor the next quarter, 6 analysts are estimating revenue of $11.04M. There is a high estimate of $19.5M for the next quarter, whereas the lowest estimate is $2.89M.
A total of 6 analysts have provided revenue estimates for CLLS’s current fiscal year. The highest revenue estimate was $109.46M, while the lowest revenue estimate was $34.66M, resulting in an average revenue estimate of $52.07M. In the same quarter a year ago, actual revenue was $8.58MBased on 6 analysts’ estimates, the company’s revenue will be $63.92M in the next fiscal year. The high estimate is $158.83M and the low estimate is $11.55M.
